Selecta Biosciences, Inc. (SELB) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Selecta Biosciences, Inc. (NASDAQ:SELB) released its quarterly earnings data on Friday. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.01, Bloomberg Earnings reports. Selecta Biosciences had a negative net margin of 715.40% and a negative return on equity of 76.21%. The business had revenue of $0.03 million for the quarter.

Selecta Biosciences (NASDAQ:SELB) traded down 7.66% on Friday, reaching $15.67. 109,680 shares of the company’s stock were exchanged. Selecta Biosciences has a 1-year low of $10.27 and a 1-year high of $28.00. The firm’s 50 day moving average is $18.29 and its 200 day moving average is $15.01.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.thestockobserver.com/2017/08/12/selecta-biosciences-inc-selb-posts-quarterly-earnings-results-beats-expectations-by-0-01-eps.html.

A number of research analysts have issued reports on the stock. ValuEngine upgraded shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Friday, June 30th. Zacks Investment Research upgraded shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, Canaccord Genuity set a $25.00 target price on shares of Selecta Biosciences and gave the company a “buy” rating in a report on Wednesday, July 26th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Selecta Biosciences currently has an average rating of “Buy” and a consensus target price of $26.00.

In other Selecta Biosciences news, COO Lloyd P. Johnston sold 5,959 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $19.10, for a total transaction of $113,816.90. Following the completion of the sale, the chief operating officer now directly owns 7,565 shares in the company, valued at approximately $144,491.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Timothy A. Springer acquired 338,791 shares of the firm’s stock in a transaction on Tuesday, June 27th. The shares were acquired at an average price of $17.71 per share, with a total value of $5,999,988.61. Following the completion of the transaction, the director now directly owns 355,413 shares in the company, valued at approximately $6,294,364.23. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 355,413 shares of company stock valued at $6,232,567 and sold 321,819 shares valued at $4,765,494.

Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its stake in shares of Selecta Biosciences by 46.8% in the second quarter. JPMorgan Chase & Co. now owns 358,846 shares of the company’s stock valued at $7,126,000 after buying an additional 114,477 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Selecta Biosciences by 119.9% in the second quarter. Bank of New York Mellon Corp now owns 32,400 shares of the company’s stock valued at $644,000 after buying an additional 17,664 shares in the last quarter. Vivo Capital LLC purchased a new stake in shares of Selecta Biosciences during the second quarter valued at about $22,227,000. Rhumbline Advisers purchased a new stake in shares of Selecta Biosciences during the second quarter valued at about $239,000. Finally, Schwab Charles Investment Management Inc. purchased a new stake in shares of Selecta Biosciences during the second quarter valued at about $392,000. Institutional investors and hedge funds own 46.27% of the company’s stock.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply